Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | PHASE1 | RECRUITING | 292 | — | — | Jun 1, 2020 | Jun 1, 2027 | Aug 15, 2025 | 20 | United States, Australia +1 |
Incidence and severity of AEs and SAEs
Incidence and severity of AEs and SAEs
Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.
| Arm | Type | Description |
|---|---|---|
| BCA101 Monotherapy | EXPERIMENTAL | Route: IV Infusion Frequency: QW Current Dose: 1500mg |
| BCA101 + pembrolizumab | EXPERIMENTAL | Route: IV Infusion Frequency: Q3W Dose: 200mg |
| Name | Type | Description |
|---|---|---|
| BCA101 | DRUG | EGFR/TGFβ fusion monoclonal antibody |
| Pembrolizumab | DRUG | anti-PD-1 |
Inclusion Criteria: * Patient must have measurable disease amendable to biopsy and be willing to undergo both a pre-treatment and on-treatment biopsy, as well as provide archival tumor if available from the primary tumor (a paraffin embedded tumor tissue block sufficient to obtain at least 10 secti...